32 days to first decision for reviewed manuscripts only
20 days to first decision for all manuscripts
59 days from submission to acceptance
12 days from acceptance to publication
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatmen...
Citation: Experimental Hematology & Oncology 2021 10:46